BRD-810 is a Highly Selective MCL1 Inhibitor with Optimized in Vivo Clearance and Robust Efficacy in Solid and Hematological Tumor Models.
Ulrike Rauh,Guo Wei,Michael Serrano-Wu,Georgios Kosmidis,Stefan Kaulfuss,Franziska Siegel,Kai Thede,James McFarland,Christopher T Lemke,Nicolas Werbeck,Katrin Nowak-Reppel, Sabine Pilari,Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange,Jennifer Roth, Douglas Daniels,Virendar K Kaushik,Brian Hubbard,Karl Ziegelbauer,Todd R Golub Nature cancer（2024）
AI 理解论文
溯源树
样例
